CASI Pharmaceuticals, Inc. - CASI
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 23, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Nimish Shah | 9.2% | 1,987,259 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 9.2% | 1,987,259 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Foresite Capital Fund VI LP | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Foresite Capital Management VI LLC | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | James Tananbaum | 0.0% | 0 | View |
| Feb 10, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Jan 29, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Jan 20, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Jan 20, 2026 | SCHEDULE 13D/A | — | 100.0% | — | View |
| Jan 09, 2026 | SCHEDULE 13D/A | — | 30.0% | — | View |
| Dec 18, 2025 | SCHEDULE 13D/A | — | — | — | View |
| Dec 17, 2025 | SCHEDULE 13D/A | — | — | — | View |
| Nov 26, 2025 | SCHEDULE 13G | Chen Zhenfeng | 11.0% | 2,255,636 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Fund VI LP | 6.3% | 979,956 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Management VI LLC | 6.3% | 979,956 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | James Tananbaum | 6.3% | 979,956 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.